trending Market Intelligence /marketintelligence/en/news-insights/trending/oql7gCKs795nKE6ZvlYbVA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Novartis to buy CellforCure to boost cell and gene therapy production capacity

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Novartis to buy CellforCure to boost cell and gene therapy production capacity

Novartis AG said it agreed to buy CELLforCURE, a private French company, to increase its capacity to make complex cell and gene therapies amid competition in the field.

The Swiss pharmaceutical giant plans to purchase CellforCure's share capital from LFB SA, another private French company. The acquisition would bring a cell and gene manufacturing plant in Les Ulis, France, into a network of facilities including sites in Morris Plains, N.J., and Stein, Switzerland.

Financial terms were not disclosed in a Dec. 20 press release from Novartis. The acquisition is subject to usual and customary closing conditions and will be funded through available cash if approved. Novartis expects to close the deal in the first half of 2019.

The proposed acquisition follows Novartis' July 2018 contract with CellforCure to produce CAR-T cell therapies including Kymriah, the first to reach the U.S. market. Kymriah competes with Gilead Sciences Inc.'s Yescarta, and more companies are pursuing development of CAR-T cell therapies.

CellforCure also has contracted with Cellectis SA, a French biopharmaceutical company, to manufacture cell therapies. The press release did not specify the impact of the transaction on any contracts with companies other than Novartis.

Novartis has been shoring up its manufacturing and supply lines as the drugmaker embarks on a strategy relying on pioneering technologies to drive some 20% of revenue within the next five years. Those deals include an agreement with Cellular Biomedicine Group Inc. to produce and supply Kymriah in China, as well as collaborations in Germany and Japan.